Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations.
Bisphosphonates (BPs) are drugs widely used in the treatment of various bone diseases. BPs localize to bone mineral, and their concentration in resorption lacunae could reach almost millimolar levels. Bone alkaline phosphatase (ALP) is a membrane-bound exoenzyme that has been implicated in bone formation and mineralization. In this study, we investigated the possible direct effect of three N-containing BPs (alendronate, pamidronate, and zoledronate) on the specific activity of bone ALP obtained from an extract of UMR106 rat osteosarcoma cells. Enzymatic activity was measured by spectrophotometric detection of p-nitrophenol product and by in situ visualization of ALP bands after an electrophoresis on cellulose acetate gels. Because ALP is a metalloprotein that contains Zn2+ and Mg2+, both of which are necessary for catalytic function, we also evaluated the participation of these divalent cations in the possible effect of BPs on enzymatic activity. All BPs tested were found to dose-dependently inhibit spectrophotometrically measured ALP activity (93-42% of basal) at concentrations of BPs between 10-5 M and 10-4 M, the order of potency being zoledronate approximately equals alendronate > pamidronate. However, coincubation with excess Zn2+ or Mg2+ completely abolished this inhibitory effect. Electrophoretic analysis rendered very similar results: namely a decrease in the enzymatic activity of the bone-ALP band by BPs and a reversion of this inhibition by divalent cations. This study shows that N-containing BPs directly inhibit bone-ALP activity, in a concentration range to which this exoenzyme is probably exposed in vivo. In addition, this inhibitory effect is most possibly the result of the chelation of Zn2+ and Mg2+ ions by BPs.
Vaisman
Diego N
DN
Cátedra de Bioquímica Patológica, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, 47 y 115(1900) La Plata, Argentina.
McCarthy
Antonio D
AD
Cortizo
Ana M
AM
D019386:Alendronate / Q000494:pharmacology; D000469:Alkaline Phosphatase / Q000037:antagonists & inhibitors*; D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy; D001842:Bone and Bones / Q000201:enzymology*; D002413:Cations, Divalent / Q000494:pharmacology*; D004164:Diphosphonates / Q000494:pharmacology*; D007093:Imidazoles / Q000494:pharmacology; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000302:isolation & purification; D008274:Magnesium / Q000494:pharmacology*; D010006:Osteoblasts / Q000201:enzymology; D012516:Osteosarcoma / Q000201:enzymology; D000077268:Pamidronate; D051381:Rats; D014407:Tumor Cells, Cultured; D015032:Zinc / Q000494:pharmacology*; D000077211:Zoledronic Acid
D002413:Cations, Divalent; D004164:Diphosphonates; D007093:Imidazoles; D007527:Isoenzymes; D000077211:Zoledronic Acid; D000469:Alkaline Phosphatase; D008274:Magnesium; D015032:Zinc; D000077268:Pamidronate; D019386:Alendronate